FDA Adverse Event Malfunction Summary report: N

ARCHITECT ANTI-HCV REAGENT KIT

MDR report key: 15222679 · Received August 13, 2022

Report

Report Number
3002809144-2022-00281
Event Type
Malfunction
Date Received
August 13, 2022
Date of Event
July 30, 2022
Report Date
September 10, 2022
Manufacturer
ABBOTT GMBH
Product Code
MZO
PMA / PMN Number
N/A
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

THIS REPORT IS BEING FILED ON AN INTERNATIONAL PRODUCT, ARCHITECT ANTI-HCV, LIST NUMBER: 06C37, THAT HAS A SIMILAR PRODUCT DISTRIBUTED IN THE US, LIST NUMBER: 01L79. AN EVALUATION IS IN PROCESS. A FOLLOW-UP REPORT WILL BE SUBMITTED WHEN THE EVALUATION IS COMPLETE.

Additional Manufacturer Narrative · 0

AFTER FURTHER EVALUATION, THE SUSPECT MEDICAL DEVICE WAS CHANGED FROM ARCHITECT ANTI-HCV, LIST 06C37-78, ABBOTT GMBH, WIESBADEN, GERMANY TO THE ARCHITECT I2000SR PROCESSING MODULE, LIST 03M74-02, ABBOTT LABORATORIES, IRVING, TEXAS, USA. MDR NUMBER 3016438761-2022-00411-00 HAS BEEN SUBMITTED AND ALL FURTHER INFORMATION WILL BE DOCUMENTED UNDER THAT MDR NUMBER.THIS FOLLOW UP IS BEING SUBMITTED TO INCLUDE THE INITIAL CODING IN SECTION H6 FOR COMPONENT CODE, TYPE OF INVESTIGATION, INVESTIGATION FINDINGS AND INVESTIGATION CONCLUSIONS THAT WERE NOT INCLUDED IN THE INITIAL REPORT.

Description of Event or Problem · 0

THE CUSTOMER OBSERVED FALSE NONREACTIVE ARCHITECT ANTI-HCV RESULT FOR ONE PATIENT THAT DID NOT MATCH WITH THE PATIENT¿S HISTORICAL RESULTS WHICH WERE POSITIVE. NO SPECIFIC DATA OR PATIENT INFORMATION WAS PROVIDED. NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1817125 ARCHITECT ANTI-HCV REAGENT KIT ASSAY, ENZYME LINKED IMMUNOSORBENT, HEPATITIS C VIRUS MZO ABBOTT GMBH 35518BE01

Patients

Seq Age Sex Outcome Treatment
1 Unknown ARC I2000SR INST, 03M74-02, (B)(6).| ARC I2000SR INST, 03M74-02,(B)(6).